Genmab — August 2019
-
Jo, der burde være offentliggjort salgstal i dag baseret på optalte receptudskrivninger af Symphony Health. Men det er kun for betalende kunder. Når vi her på PI engang imellem får oplyst tallet er det kun fordi nogen har været så venlig at lade det sive. Vi kender heller ikke tallet for juni.
-
Key statistics for ALL https://www.cancer.org/cancer/acute-lymphocytic-leukemia/about/key-statistics.html
-
Genmab A/S (Nasdaq: GMAB) announced today that preliminary data from the Phase I/II trial of enapotamab vedotin in advanced non-small cell lung cancer (NSCLC) has been accepted for oral presentation at the International Association for the Study of Lung Cancer 2019 World Conference on Lung Cancer (IASLC 2019 WCLC) taking place from September 7-10, 2019 in Barcelona, Spain
-
God morgen.
-
Fra seneste CC omkring AXL
: With overexpressed AXL in lung cancer that was already quite clear during the dose escalation. And we have expanded the expansion cohort by a very large number of patients, and we hope to present you the initial, I think, 26 or so patient's worth of data and then we will -- we hope to present definitely at a response-rate level. And I think it's a bit too early to look at durability, Matthew -
But you're also developing an assay to actually screen patients for AXL expression, potentially for the next clinical study, and I think that will all become quite clear at the data presentation at an upcoming medical conference, and we will flag that up to you in the coming weeks.
-
Fra ASCO abstract: Results: 47 pts with NSCLC (n=8), melanoma (n=9), ovarian (n=22), cervical (n=3) and endometrial (n=5) cancer enrolled in ph1 (1Q3W n=32; 3Q4W n=15). Most pts were female (87%), White (94%) and aged <65 y (66%). MTD was 2.2 mg/kg in 1Q3W arm and 1.0 mg/kg in 3Q4W arm; RP2D was 2.2 mg/kg 1Q3W. EnaV median elimination half-life: 0.9–2.2 d across doses/schedules. In 47 enrolled pts, there were 6 DLTs (Table). Most common AEs (any G; ≥40% pts) were fatigue (64%), nausea (57%)
-
, diarrhea (47%), vomiting (45%) and decreased appetite (43%). 3 pts (1Q3W arm) had partial response (1 NSCLC [2.2 mg/kg dose]; 2 ovarian [1.5 and 2.4 mg/kg dose levels]). Conclusions: The RP2D of single agent EnaV in pre-treated pts with solid tumors was 2.2 mg/kg 1Q3W. EnaV had encouraging preliminary anti-tumor activity and will be evaluated in 7 ph2a expansion cohorts to further assess safety, tolerability, PK, anti-tumor activity and Axl expression. Funding: Genmab A/S. Clinical trial infor
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind